September 2013Introduction
Transplant associated hyperglycemia (TAHG) comprises new-onset diabetes after transplantation (NODAT), im- paired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), all of which are associated with increased morbidity and mortality in kidney transplant recipients (KTRs) (1–3). NODAT confers a high risk for premature graft failure and also increased cardiovascular mortality (4,5). Current therapeutic strategies against NODAT are largely based on treatment guidelines for type 2 diabetes mellitus (DM) (6). While type 2 DM is often considered a problem of increased insulin resistance,